RSV Bronchiolitis.

Slides:

Advertisements

Similar presentations

Management. ACUTE UNCOMPLICATED PYELONEPHRITIS Goals of Treatment To eradicate organisms invading the renal parenchyma To anticipate the need to treat.

Advertisements

JOURNAL CLUB M M Khan ST6. 4 year 2 nd wheezy episode O/E mild distress. Sats borderline Management : Salbutamol Ipratropium bromide Steroid.

Pertussis Kate Goheen March 25, 2009 Weill Cornell Medical College Class of 2010.

Bronchiolitis and Synagis. CONTINUITY CLINIC Pretest Which of the following children should receive RSV prophylaxis during RSV season? Which of the following.

Prostacyclin Promoter Polymorphism is Associated with Severity of Infant Respiratory Viral Infection S Van Driest 1, T Gebretsadik 3, P Moore 2, S Reiss.

Insert Program or Hospital Logo Introduction The Respiratory Syncytial virus (RSV) was discovered in 1956 and has been since recognized as one of the most.

Immunoprophylaxis for Prevention of Severe RSV Bronchiolitis Ma. Teresa C. Ambat, MD Neonatology-TTUHSC11/21/2008.

Respiratory Syncytial Virus A CHILDHOOD MALADY. History  RSV,which stands for Respiratory Syncytial Virus, is a severe disease that can lead to a lower.

Bordetella (pertussis) (whooping cough) bacterial respiratory childhood infections B. Pertussis B. parapertussis.

Delmar Learning Copyright © 2003 Delmar Learning, a Thomson Learning company Chapter 32 Poverty.

Age appears to be a significant effect modifier of the impact of palivizumab on RSV hospitalization risk. Given the rapid decrease of RSV risk with increasing.

RSV RT 265. Respiratory Syncytial Virus Manifests primarily as: Bronchiolitis Bronchiolitis Viral pneumonia Viral pneumonia Leading cause of lower respiratory.

July 29, Most common pathogen causing lower airway disease in infants and toddlers 90,000 hospitalizations/year $700 million/year for children.

Paramyxoviruses Stanley I. Martin, MD Associate Professor Division of Infectious Diseases.

RSV: RESPIRATORY SYNCYTIAL VIRUS Barbara Woodall.

Bronchiolitis Abdullah M. Al-Olayan MBBS, SBP, ABP. Assistant Professor of Pediatrics. Pediatric Pulmonologist.

$1 Million $500,000 $100,000 $50,000 $25,000 $10,000 $5,000 $1,000.

Policy Change and Public Health Impact

RESPIRATORY SYNCYTIAL VIRUS (RSV)

Figure 4 Monthly all-cause (A-C) and pneumonia and influenza (P&I) mortality rates among Japanese children aged 5–9 years. Vertical dotted lines, January.

Sites of Action in Coagulation System Novel Factor Xa and DT Inhibitors.

A Framework for Diagnosing and Treating CTEPH

This program will include a discussion of off-label treatment not approved by the FDA for use in the United States.

Paula Chilvers GPST2 November 2017

Essential Updates in Atopic Dermatitis:

Diagnosing Vertebral Fractures

This talk will follow the topical structure suggested by the ABP:

NOACs in Clinical Practice: Are They All the Same?

Ask the Onychomycosis Expert, Part 2

Protecting Patients With Varicose Veins

Update on Clostridium difficile Infection

The Role of Imaging in Diagnosing IPF Hands-On Case Studies

This Program Will Discuss

Before and After: Patient Cases in Onychomycosis

Surveying the Safety of NOACs in the Real World

PAH Therapy Revisited.

Improving Narcolepsy Diagnosis

The State of Pneumococcal Disease Prevention

Time to Take Gout Seriously

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

Wheezy Infant Prof.Dr.Reha Cengizlier

Initiating Pre-exposure Prophylaxis The PrEP Checklist

A Case-based Approach to RSV Disease

Diagnosing Nontuberculous Mycobacterial Disease

From Start to Finish: Initial and Ongoing Care for Men Receiving PrEP

Pseudobulbar Affect or Psychiatric Condition?

Maternal Pertussis vaccination: Giving Newborns a head start

Extraordinary Cases of VTE Prevention in Patients With Cancer

Management of Systematic Lupus Erythematosus

Introduction to AD. Practical Approaches to the Identification of Alzheimer Disease in Primary Care.

Preventing Clinical Events in PAH

TB epidemiological situation in Kyrgyzstan

Iron Deficiency in Heart Failure

Etiology and Incidence Pathophysiology Hemophilia is due to a defect in thrombin generation on the platelet surface.

Incorporating Prostacyclins Into Practice

The Rising Crisis of Prediabetes Diagnosis and Management of the Patient With Prediabetes.

Treating Atypical Hemolytic Uremic Syndrome A Case Discussion

So Many Guidelines, So Little Time:

AMD Therapy: Where Are We Now and Where Are We Going?

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

MS, Age, and Immune Function

Tardive Dyskinesia 101.

Tuomas Jartti, MD, James E. Gern, MD

My PAH Patient.

BRONCHIOLITIS. BRONCHIOLITIS ACUTE Viral BRONCHIOLITIS Common disease of the lower respiratory tracr in infants.usually most cases < 2 years. Inflammatory.

Evidence-based management of bronchiolitis.

Treating Pulmonary Embolism Today

Presentation transcript:

RSV Bronchiolitis

Program Goals

Incidence of RSV Infection

RSV Morbidity and Mortality

High-Risk Infants and Children

Pathophysiology of RSV Infection

Clinical Presentation of RSV Illness

Differential Diagnosis of RSV Bronchiolitis

Laboratory Diagnosis

Pulmonary Sequelae of RSV Bronchiolitis

Pulmonary Sequelae of RSV Bronchiolitis (cont)

Treatment of RSV Bronchiolitis

Treatment of RSV Bronchiolitis (cont)

Treatment of RSV Bronchiolitis (cont)

Preventing RSV Illness

Efficacy of Palivizumab

Efficacy of Palivizumab (cont)

Candidates for Immunoprophylaxis

Candidates for Immunoprophylaxis (cont)

Maximum Number of Monthly Doses of Palivizumab

Maximum Number of Monthly Doses of Palivizumab (cont)

Does Immunoprophylaxis Protect Against Subsequent Wheezing?

Passive Smoking and RSV Risk

Abbreviations